The clinical value of combined 68Ga-SSA/18F-FDG PET/CT imaging in neuroendocrine neoplasms
10.3760/cma.j.issn.2095-2848.2020.01.012
- VernacularTitle: 68Ga-SSA/18F-FDG PET/CT联合显像在神经内分泌肿瘤诊治中的应用价值
- Author:
Shuai ZHAO
1
;
Chao CHENG
;
Changjing ZUO
Author Information
1. Department of Nuclear Medicine, Changhai Hospital, Navy Medical University, Shanghai 200433, China
- Publication Type:Review
- Keywords:
Neuroendocrine tumors;
Somatostatin;
Gallium radioisotopes;
Positron-emission tomography;
Tomography, X-ray computed;
Deoxyglucose;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2020;40(1):47-51
- CountryChina
- Language:Chinese
-
Abstract:
Neuroendocrine neoplasms (NEN) are tumors that originate from neuroendocrine cells or peptidergic neurons. NEN can be found in a variety of organs with high heterogeneity in pathology and large difference in prognosis. Conventional imaging methods and pathological biopsy have important roles in the diagnosis of NEN, while both of them have limitations. Most NEN cells highly express several peptide receptors, especially somatostatin receptors (SSTR). Moreover, some of them have high glycolysis activity because of high proliferative activity. 68Ga-somatostatin analogs (68Ga-SSA) combined with 18F-fluorodeoxyglucose (18F-FDG) PET/CT imaging can comprehensively evaluate both the expression of SSTR and the activity of glycolysis in NEN, providing effective information for diagnosis, treatment, monitoring and prognosis. This review summarizes the current studies of combined 68Ga-SSA/18F-FDG PET/CT imaging in patients with NEN.
